Wolfe Research Begins Coverage on Centessa Pharmaceuticals (NASDAQ:CNTA)

Equities research analysts at Wolfe Research started coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm set an “outperform” rating and a $40.00 price target on the stock. Wolfe Research’s price target suggests a potential upside of 56.92% from the stock’s previous close.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Stephens initiated coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price on the stock. Guggenheim boosted their price objective on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 21st. Finally, TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.64.

Centessa Pharmaceuticals Stock Up 4.0%

Shares of NASDAQ CNTA opened at $25.49 on Tuesday. The business has a 50-day moving average of $24.23 and a two-hundred day moving average of $23.40. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of -13.93 and a beta of 1.56. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Insider Activity

In related news, insider Mario Alberto Accardi sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the transaction, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Iqbal J. Hussain sold 38,951 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the sale, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 49,961 shares of company stock worth $1,304,878 over the last quarter. 7.09% of the stock is currently owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. TD Waterhouse Canada Inc. purchased a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Centessa Pharmaceuticals in the fourth quarter valued at about $36,000. T. Rowe Price Investment Management Inc. raised its holdings in shares of Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares during the period. Wells Fargo & Company MN lifted its position in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr purchased a new position in Centessa Pharmaceuticals in the 4th quarter worth approximately $100,000. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.